Cargando…

Real‐Time 3‐Dimensional Echocardiographic Assessment of Effective Regurgitant Orifice Area in Dogs With Myxomatous Mitral Valve Disease

BACKGROUND: Effective regurgitant orifice area (EROA), calculated from the vena contracta width (VCW) as the narrowest portion of the proximal regurgitant jet, might be used to estimate severity of mitral regurgitation. However, this simplified assumption only holds when the EROA is circular, which...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tidholm, A., Bodegård‐Westling, A., Höglund, K., Häggström, J., Ljungvall, I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	SMALL ANIMAL
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354031/ https://www.ncbi.nlm.nih.gov/pubmed/28109120 http://dx.doi.org/10.1111/jvim.14642

Ejemplares similares

Comparison between real‐time 3‐dimensional and 2‐dimensional biplane echocardiographic assessment of left atrial volumes in dogs with myxomatous mitral valve disease
por: Tidholm, Anna, et al.
Publicado: (2019)

Diagnostic Value of Selected Echocardiographic Variables to Identify Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease
por: Tidholm, A., et al.
Publicado: (2015)

The Mitral INsufficiency Echocardiographic score: A severity classification of myxomatous mitral valve disease in dogs
por: Vezzosi, Tommaso, et al.
Publicado: (2021)

Echocardiographic Estimates of Right Ventricular Systolic Function in Dogs with Myxomatous Mitral Valve Disease
por: Chapel, E.H., et al.
Publicado: (2017)

Echocardiographic predictors of first onset of atrial fibrillation in dogs with myxomatous mitral valve disease
por: Baron Toaldo, Marco, et al.
Publicado: (2020)

Echocardiographic estimation of left ventricular‐arterial coupling in dogs with myxomatous mitral valve disease
por: Osuga, Tatsuyuki, et al.
Publicado: (2021)

Reproducibility of echocardiographic indices of left atrial size in dogs with subclinical myxomatous mitral valve disease
por: Hsue, Weihow, et al.
Publicado: (2020)

Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study
por: Boswood, A., et al.
Publicado: (2017)

Prognostic value of echocardiographic indices of left atrial morphology and function in dogs with myxomatous mitral valve disease
por: Baron Toaldo, Marco, et al.
Publicado: (2018)

Echocardiographic indices and severity of mitral regurgitation in dogs with preclinical degenerative mitral valve disease
por: Larouche‐Lebel, Éva, et al.
Publicado: (2019)

Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study
por: Boswood, Adrian, et al.
Publicado: (2020)

The chromogranin A-derived peptides catestatin and vasostatin in dogs with myxomatous mitral valve disease
por: Höglund, Katja, et al.
Publicado: (2020)

Utility of radiographic measurements to predict echocardiographic left heart enlargement in dogs with preclinical myxomatous mitral valve disease
por: Poad, Megan H., et al.
Publicado: (2020)

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial
por: Boswood, A., et al.
Publicado: (2016)

Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease
por: Kim, H.‐S., et al.
Publicado: (2016)

Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration
por: Reimann, M.J., et al.
Publicado: (2017)

Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs
por: Nakamura, K., et al.
Publicado: (2017)

Prevalence and risk factors for atrial fibrillation in dogs with myxomatous mitral valve disease
por: Guglielmini, Carlo, et al.
Publicado: (2020)

Radiographic quantification of left atrial size in dogs with myxomatous mitral valve disease
por: Lam, Christopher, et al.
Publicado: (2021)

Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease
por: McManamey, Anna K., et al.
Publicado: (2023)

Utility of Tissue Doppler Imaging in the Echocardiographic Evaluation of Left and Right Ventricular Function in Dogs with Myxomatous Mitral Valve Disease with or without Pulmonary Hypertension
por: Baron Toaldo, M., et al.
Publicado: (2016)

Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease
por: Druzhaeva, Natalia, et al.
Publicado: (2021)

Prognostic value of serum cystatin C concentration in dogs with myxomatous mitral valve disease
por: Iwasa, Naoki, et al.
Publicado: (2023)

Assessment of Left Atrial Deformation and Function by 2‐Dimensional Speckle Tracking Echocardiography in Healthy Dogs and Dogs With Myxomatous Mitral Valve Disease
por: Baron Toaldo, M., et al.
Publicado: (2017)

Effect of Body Weight on Echocardiographic Measurements in 19,866 Pure‐Bred Cats with or without Heart Disease
por: Häggström, J., et al.
Publicado: (2016)

Effect of feline characteristics on plasma N‐terminal‐prohormone B‐type natriuretic peptide concentration and comparison of a point‐of‐care test and an ELISA test
por: Hanås, Sofia, et al.
Publicado: (2020)

Prognostic value of left ventricular‐arterial coupling estimated using echocardiography in dogs with myxomatous mitral valve disease
por: Osuga, Tatsuyuki, et al.
Publicado: (2021)

Prognostic value of pulmonary vascular resistance estimated by echocardiography in dogs with myxomatous mitral valve disease and pulmonary hypertension
por: Yuchi, Yunosuke, et al.
Publicado: (2023)

Radiographic lung congestion scores in dogs with acute congestive heart failure caused by myxomatous mitral valve disease
por: Koster, Liza, et al.
Publicado: (2023)

Polymorphisms in the serotonin transporter gene and circulating concentrations of neurotransmitters in Cavalier King Charles Spaniels with myxomatous mitral valve disease
por: Reimann, Maria J., et al.
Publicado: (2021)

Breeding Restrictions Decrease the Prevalence of Myxomatous Mitral Valve Disease in Cavalier King Charles Spaniels over an 8‐ to 10‐Year Period
por: Birkegård, A.C., et al.
Publicado: (2016)

Influence of clinical setting and cat characteristics on indirectly measured blood pressure and pulse rate in healthy Birman, Norwegian Forest, and Domestic Shorthair cats
por: Hanås, Sofia, et al.
Publicado: (2021)

The classical and alternative circulating renin‐angiotensin system in normal dogs and dogs with stage B1 and B2 myxomatous mitral valve disease
por: Hammond, Hillary H., et al.
Publicado: (2023)

Evaluation of urinary neutrophil gelatinase‐associated lipocalin to detect renal tubular damage in dogs with stable myxomatous mitral valve disease
por: Troia, Roberta, et al.
Publicado: (2022)

Comparison of the mitral valve morphologies of Cavalier King Charles Spaniels and dogs of other breeds using 3D transthoracic echocardiography
por: Menciotti, Giulio, et al.
Publicado: (2018)

Influence of concurrent lower respiratory tract disease on point‐of‐care lung ultrasound in small‐breed dogs with myxomatous mitral valve disease
por: Lam, Man‐Cham, et al.
Publicado: (2022)

Prognostic Value of Right Ventricular Tei Index in Dogs with Myxomatous Mitral Valvular Heart Disease
por: Nakamura, K., et al.
Publicado: (2016)

Cardiorenal and endocrine effects of synthetic canine BNP1‐32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease
por: Yata, Mariko, et al.
Publicado: (2019)

Effect of prespecified therapy escalation on plasma NT‐proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease
por: Hezzell, Melanie J., et al.
Publicado: (2018)

A prospective, randomized, double‐blind, placebo‐controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease
por: Newhard, Daniel K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ef7s5ej7aclaogpuamn444sdju